Published in final edited form as:

Biochem Pharmacol. 2007 September 1; 74(5): 768–779.

Role of Adenosine A₃ Receptors on CA1 Hippocampal Neurotransmission During Oxygen-Glucose Deprivation Episodes of Different Duration

Anna Maria Pugliese^a, Elisabetta Coppi^a, Rosaria Volpini^b, Gloria Cristalli^b, Renato Corradetti^a, Lak Shin Jeong^c, Kenneth A. Jacobson^{d,*}, and Felicita Pedata^{a,*}

^aDepartment of Preclinical and Clinical Pharmacology, University of Florence, Viale Pieraccini 6, 50139 Firenze, Italy

^bDepartment of Chemical Sciences, University of Camerino, 62032 Camerino, Italy

^cLaboratory of Medicinal Chemistry, College of Pharmacy, Ewha Womans University, Seoul 120-750, Korea

^dMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0810, USA

Abstract

The role of adenosine A₃ receptors in synaptic transmission under severe (7 min) and shorter (2-5 min) ischemic conditions, obtained by oxygen and glucose deprivation (OGD), was investigated in rat hippocampal slices. The effects of selective A₃ agonists or antagonists were examined on field excitatory postsynaptic potentials (fEPSPs) extracellularly recorded at the dendritic level of the CA1 pyramidal region. The novel, selective A₃ antagonist LJ1251 ((2*R*,3*R*,4*S*)-2-(2-chloro-6-(3-iodobenzylamino)-9*H*-purin-9-yl)tetrahydrothiophene-3,4-diol, 0.1-10 nM) protected hippocampal slices from irreversible fEPSP depression induced by severe OGD and prevented or delayed the appearance of anoxic depolarization. Similar results were obtained when severe OGD was carried out with a long, receptor-desensitizing exposure to various selective A₃ agonists: 5'-N-methylcarboxamidoadenosine derivatives Cl-IB-MECA (N⁶-(3-iodobenzyl)-2-chloro), VT72 (N⁶-methoxy-2-phenylethynyl), VT158 (N⁶-methoxy-2-phenylethynyl), VT160 (N⁶-methoxy-2-(2-pyridinyl)-ethynyl), and VT163 (N⁶-methoxy-2-*p*-acetylphenylethynyl) and AR132 (N⁶-methyl-2-phenylethynyladenosine).

The selective A₃ antagonist MRS1523 (3-propyl-6-ethyl-5-[(ethylthio)carbonyl]-2-phenyl-4-propyl-3-pyridine carboxylate, 100 nM) reduced fEPSP depression evoked by 2-min OGD and induced a faster recovery of fEPSP amplitude after 5-min OGD. Similar results were obtained for 2- or 5-min OGD applied in the presence of each of the A₃ agonists tested. Shorter exposure to A₃ agonists significantly delayed the recovery of fEPSP amplitude after 5-min OGD.

This indicates that A₃ receptors, stimulated by selective A₃ agonists, undergo desensitization during OGD. It is inferred that CA1 hippocampal A₃ receptors stimulated by adenosine released during brief ischemia (2 and 5 min) might exert A₁-like protective effects on neurotransmission. Severe ischemia would transform the A₃ receptor-mediated effects from protective to injurious.

*Authors for correspondence: Prof. Felicita Pedata, Department of Preclinical and Clinical Pharmacology, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy, Telephone: + 39 055 4271.262, Fax: + 39 055 4271.280, E-mail address: felicita.pedata@unifi.it, Dr. Kenneth A. Jacobson, Chief, Molecular Recognition Section, Laboratory of Bioorganic Chemistry, NIDDK, Bldg. 8A, Rm. B1A-19, Bethesda, MD USA, (301) 496-9024; FAX (301) 480-8422, E-mail address: kajacobs@helix.nih.gov

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

purines; G protein-coupled receptors; cerebral ischemia; hippocampal slices; field EPSP; desensitization

1. Introduction

Adenosine acts in the brain by activation of four receptor subtypes, A₁, A_{2A}, A_{2B}, and A₃, all coupled to their effector systems through heterotrimeric G proteins [1]. Of the four adenosine receptor subtypes, the adenosine A₃ receptor is the most recently cloned [2]. A₃ receptors have a widespread distribution in the rat brain [3] and in the hippocampus are preferentially expressed on nerve terminals [4,5]. The expression of A₃ receptors in the brain is lower than that of other adenosine receptor subtypes [6], and the affinity for adenosine, calculated from binding experiments in rat brain membranes (6.5 μ M [2]), is lower than that of A₁ [7] and A_{2A} [8] receptors. However, during ischemic conditions *in vivo* [9] and *in vitro* [10] adenosine extracellular concentrations may be sufficiently high to activate adenosine A₃ receptors, which may play a role in brain ischemia (see [11,12]).

We recently demonstrated that selective antagonism of A₃ receptors facilitates the recovery of synaptic activity induced by ischemic preconditioning in rat hippocampal slices [13]. A harmful role of A₃ receptors during *in vitro* oxygen glucose deprivation (OGD) was confirmed by the observation that blocking the A₃ adenosine receptor consistently abolishes or delays the occurrence of anoxic depolarization (AD) and significantly protects from the irreversible disruption of excitatory neurotransmission caused by a severe ischemic episode [14]. These results agree with the observation that acute administration of a selective adenosine A₃ agonist exacerbates the damage elicited by global ischemia in the gerbil [15]. On the contrary, it was demonstrated that chronic preischemic administration of an A₃ agonist protects against ischemic neuronal damage [15]. This effect may be attributable to desensitization of A₃ receptors. In fact, both human and rat A₃ receptors are desensitized within a few minutes after agonist exposure [16-21].

Contrary to the above information, Hentschel *et al.* [22] demonstrated that under hypoxic conditions, selective activation of A₃ adenosine receptors brings about an inhibition of excitatory neurotransmission on cortical neurons, indicating that A₃ receptors may sustain the neuroprotective action of adenosine induced by A₁ receptors. Consistently with these reports, mice lacking A₃ adenosine receptors showed increased neurodegeneration in response to repeated episodes of moderate hypoxia [23] or an increase in cerebral infarction after transient ligation of the middle cerebral artery [24]. Together, these data suggest that the outcome of A₃ receptor stimulation on synaptic transmission during hypoxic/ischemic phenomena depends on the intensity and duration of stimulation.

In the present work we investigated the role of adenosine A₃ receptors during ischemia by studying the effect of A₃-selective agonists and antagonists under both prolonged (7-min) and brief (2- and 5-min) OGD episodes. Prolonged, severe episodes of OGD bring about the irreversible depression of neurotransmission and the appearance of AD [14,25], a phenomenon strictly correlated with the extent of brain damage during ischemia both *in vivo* and *in vitro* [26]. Brief periods of ischemia are followed by complete recovery of neurotransmission and imply shorter times of A₃ receptor stimulation by endogenous adenosine released during the ischemic episode [10,13,27,28].

2. Materials and Methods

All animal procedures were carried out according to the European Community Guidelines for Animal Care, DL 116/92, application of the European Communities Council Directive (86/609/EEC). Experiments were carried out on rat hippocampal slices, prepared as previously described [13].

2.1. Slice preparation

Male Wistar rats (Harlan Italy, Udine, Italy; 150–200 g body weight) were killed with a guillotine while under anesthesia with ether, and their hippocampi were rapidly removed and placed in ice-cold oxygenated (95% O₂, 5% CO₂) artificial cerebral spinal fluid (aCSF) of the following composition (mM): NaCl 124, KCl 3.33, KH₂PO₄ 1.25, MgSO₄ 2, CaCl₂ 2, NaHCO₃ 25, and D-glucose 10. Slices (400 μ m thick) were cut with a McIlwain tissue chopper (Mickle Laboratory Engineering Co. Ltd., Gomshall, UK) and kept in oxygenated aCSF for at least 1 h at room temperature. A single slice was then placed on nylon mesh, completely submerged in a small chamber (0.8 ml), and superfused with oxygenated aCSF (30–32°C) at a constant flow rate of 2 ml $\cdot$ min⁻¹. The treated solutions reached the preparation in 90 seconds and this delay was taken into account in our calculations.

2.2. Extracellular recording

Test pulses (80 μ s, 0.066 Hz) were delivered through a bipolar nichrome electrode positioned in the stratum radiatum. Evoked extracellular potentials were recorded with glass microelectrodes (2–10 M Ω , Clark Electromedical Instruments, Pangbourne, UK) filled with 150 mM NaCl and placed in the CA1 region of the stratum radiatum. Responses were amplified (BM 622, Mangoni, Pisa, Italy), digitized (sample rate, 33.33 kHz), and stored for later analysis with LTP (version 2.30D) Program [29]. Stimulus-response curves were obtained by gradual increases in stimulus strength at the beginning of each experiment, when a stable baseline of evoked response was reached. The test stimulus pulse was then adjusted to produce a field excitatory postsynaptic potential (fEPSP) whose slope and amplitude was 40% to 50% of the maximum and was kept constant throughout the experiment. The fEPSP amplitude was routinely measured and expressed as the percentage of the average amplitude of the potentials measured during the 5 min preceding exposure of the hippocampal slices to OGD. In some experiments both the amplitude and initial fEPSP slope were quantified, but because no appreciable differences between these two parameters were observed in drug effect and OGD, only the amplitude measurement is expressed in the figures.

2.3. Application of drugs and OGD

OGD was achieved by perfusing the slice for different times—brief (2 or 5 min) or prolonged (7 min)—with aCSF lacking glucose and gassed with nitrogen (95% N₂, 5% CO₂) [30]. This caused a drop in *p*O₂ in the recording chamber from $\sim$ 500 mm Hg (normoxia) to a range of 120–150 mmHg (after 2-min OGD) and of 35–75 mm Hg (after 7-min OGD) [13], measured with an ISO2 and its associated OXEL-1 probe (WPI, Aston, UK). At the end of the ischemic period, the slice was again superfused with normal, glucose-containing, oxygenated aCSF. In the Results Section and figures, the term “untreated OGD slices” referred to hippocampal slices in which OGD episodes of different duration were applied in the absence of drugs.

Area under curve (AUC) analysis was conducted to evaluate the effects of various A₃ agonists or A₃ antagonists during 5-min OGD. Because 5-min OGD elicited a complete depression of synaptic activity in both the absence and the presence of A₃ ligands, the AUC was measured and expressed as time (min), calculated from the beginning of fEPSP depression during OGD up to the recovery of fEPSP at baseline.

The selective A₃ adenosine receptor antagonists LJ1251 and MRS1523 (3-propyl-6-ethyl-5-[(ethylthio)carbonyl]-2-phenyl-4-propyl-3-pyridine carboxylate), were applied for 10 min before and during OGD and 5 min after the ischemic episode. Concentrations of the selective adenosine A₃ receptor antagonists were chosen on the basis of K_i values at the rat and human A₃ receptors [31–33]. The binding affinities of LJ1251 at the human and rat adenosine receptors are shown in Table 1. Unlike MRS1523, which was effective at submicromolar concentrations on rat A₃ receptors, LJ1251 was effective at nanomolar concentrations on both human and rat A₃ receptors.

The selective adenosine A₃ receptor agonists Cl-IB-MECA (1-[2-chloro-6-[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl-β-D-ribofuranuronamide) [34], AR132 (N⁶-methyl-2-phenylethynyladenosine), VT72 (N⁶-methoxy-2-phenylethynyladenosine), VT158 (N⁶-methoxy-2-phenylethynyl-5'-N-methylcarboxamidoadenosine), VT160 (N⁶-methoxy-2-(2-pyridinyl)-ethynyl-5'-N-methylcarboxamidoadenosine), and VT163 (N⁶-methoxy-2-*p*-acetylphenylethynyl-5'-N-methylcarboxamidoadenosine) were each applied 5 min before, during, and 2 min after OGD (long application) or for only 2 min during OGD (short application). Cl-IB-MECA has been described as a highly selective agonist for both human and rat A₃ adenosine receptors versus A₁ and A_{2A} receptors (Table 1) [32,35]. When Cl-IB-MECA and the A₃ antagonist MRS1523 were coapplied, the antagonist was always superfused 5 min before combining the two drugs. K_i values for the A₃ agonists AR132, VT72, VT158, VT160, and VT163 (synthesized at the University of Camerino, Italy, and shown in Table 1) were taken from binding experiments in CHO (Chinese hamster ovary) cells stably transfected with human recombinant adenosine receptors. The compounds have been reported to be highly selective for human A₃ adenosine receptors versus human A₁ receptors and A_{2A} receptors [36–39].

When slices were subjected to 7 min of OGD, if the recovery of fEPSP amplitude after 15 min of reperfusion with glucose-containing and normally oxygenated aCSF was ≤15% of the preischemic value, a second slice from the same rat was submitted to a 7-min OGD insult in the presence of the A₃ agonists or antagonists under investigation. To confirm the result obtained in the treated group, a third slice was taken from the same rat and another 7-min OGD was performed in control conditions, to verify that no difference between slices was caused by the time gap between the experiments.

2.4. Drugs

MRS1523 was purchased from Sigma (Milan, Italy). Cl-IB-MECA was from Tocris (Bristol, UK). The novel antagonist LJ1251 ((2*R*,3*R*,4*S*)-2-(2-chloro-6-(3-iodobenzylamino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol), structurally based on a truncated nucleoside template, was synthesized by L. Jeong, Ewha University, Seoul, Korea. AR132, VT72, VT158, VT160, and VT163 were provided by G. Cristalli, University of Camerino, Italy. Each drug was dissolved in dimethylsulfoxide (DMSO), and stock solutions were made to obtain concentrations in DMSO of 0.05% and 0.01% in aCSF, respectively. Control experiments, carried out in parallel, showed that this concentration of DMSO did not affect either fEPSP amplitude before OGD or the depression of synaptic potential induced by the subsequent OGD.

2.5. Statistical analysis

Data were analyzed with Prism 3.02 software (GraphPad Software, San Diego, CA, USA). All numerical data are expressed as the mean ± SEM. Data were tested for statistical significance with the paired two-tailed Student's *t* test or by analysis of variance (one-way ANOVA), as appropriate. When significant differences were observed, the Newman-Keuls multiple-comparison test (one-way ANOVA) was used. A value of $P < 0.05$ was considered significant.

3. Results

The role of A₃ adenosine receptors in synaptic transmission, either in normoxic conditions or during OGD episodes of different durations, was studied through extracellular recordings of fEPSPs in the CA1 region of rat hippocampal slices. Experiments were performed on a total of 208 slices taken from 121 rats.

3.1. The selective blocking of A₃ receptors by LJ1251 or MRS 1523 protected hippocampal slices from irreversible depression of fEPSP induced by 7- min OGD

The data in Fig. 1B show that 7-min OGD was a duration of ischemic insult that induced an irreversible loss of hippocampal synaptic transmission and that both selective A₃ adenosine receptor antagonists, the novel nucleoside derivative LJ1251 and the pyridine derivative MRS1523, were able to prevent this loss. LJ1251 (10 nM, n=5) did not change fEPSP amplitude under normoxic conditions (from 0.92 ± 0.1 mV in the absence to 0.94 ± 0.1 mV in the presence of the antagonist). However, it induced a significant recovery of fEPSP amplitude of $96.0 \pm 3.3\%$ (n = 5; $P < 0.001$, one-way ANOVA, Newman-Keuls multiple-comparison post hoc test) in comparison to that obtained in untreated OGD slices ($4.1 \pm 1.6\%$, n = 13). Similar results were obtained in the presence of MRS1523. MRS1523 (100 nM, n=5) did not change fEPSP amplitude under normoxic conditions (from 0.94 ± 0.06 mV in the absence to 0.92 ± 0.07 mV in the presence of the antagonist) but after 7-min OGD elicited a fEPSP recovery of $99.3 \pm 5.9\%$ (n = 5; $P < 0.001$, one-way ANOVA, Newman-Keuls multiple-comparison post hoc test versus untreated OGD slices). Fig. 1A (left panel) shows that 7-min OGD episodes always caused AD, recorded as negative d.c. shifts, with a mean peak latency of 6.6 ± 0.2 min from the beginning of ischemia and a peak amplitude of 7.5 ± 0.7 mV (n = 5). The duration of d.c. shifts was variable (range: 5-15 min) and was always accompanied by complete and irreversible disappearance of fEPSPs (Fig. 1B). In the presence of LJ1251 (10 nM, n = 5), AD was absent in all slices recorded (Fig. 1A, middle panel). Similarly, during 7-min OGD no AD appearance was recorded in the presence of MRS1523 (100 nM, n=5, Fig. 1A, right panel). These results are in agreement with our previous results showing that MRS1523 and several chemically diverse A₃ receptor antagonists prevented the irreversible failure of neurotransmission induced by 7-min OGD and induced a complete abolishment or delay of AD [14]. The protective effect of LJ1251 against OGD-evoked irreversible depression of fEPSPs was concentration dependent (Fig. 1C), with an apparent EC₅₀ value of 0.037 nM (95% confidence interval (CI) 0.026-0.053 nM).

3.2. Selective A₃ adenosine receptor agonist CI-IB-MECA also protects from the irreversible depression of neurotransmission induced by 7-min OGD

The effects of 10 nM CI-IB-MECA on fEPSP amplitude before and after 7-min OGD are shown in Fig. 2. Seven-min OGD induced an irreversible block of neurotransmission, as indicated by the absence of fEPSP amplitude recovery ($4.2 \pm 3.3\%$, n = 16) when the slices were superfused in normal oxygenated aCSF. In eight slices in which we also measured the appearance of AD, 7-min OGD episodes always caused AD, with a mean peak latency of $\sim 5.7 \pm 0.3$ min from the beginning of OGD and a peak amplitude of 7.1 ± 0.5 mV (n = 8, Fig. 2A). CI-IB-MECA (10 nM, 5 min before, during, and 2 min after OGD) did not modify fEPSP amplitude under normoxic conditions (from 1.02 ± 0.12 mV in the absence and 1.02 ± 0.14 mV in the presence of the A₃ agonist, n=15) but induced a significant fEPSP recovery after 7-min OGD ($81.5 \pm 10.5\%$, $P < 0.001$, one-way ANOVA, Newman-Keuls multiple-comparison post hoc test versus untreated OGD slices, n = 15, Fig. 2B). AD was absent in five slices out of eight tested, and it was significantly delayed in the remaining three slices (peak latency of 7.8 ± 0.2 min, peak amplitude 6.6 ± 2.2 , Fig. 2A). Similar effects on fEPSP recovery were obtained by using different A₃ agonists: AR132 (10 nM, n = 5), VT72 (10 nM, n = 8), VT158 (5 nM, n = 3), VT160 (5 nM, n = 4), and VT163 (5 nM, n = 3, Fig. 2C). No changes in fEPSP amplitude were

observed during the 5 min of drug superfusion before OGD application (from 0.83 ± 0.06 mV in the absence to 0.82 ± 0.07 mV in the presence AR132; from 0.81 ± 0.06 mV in the absence to 0.78 ± 0.07 mV in the presence VT72; from 0.80 ± 0.10 mV in the absence to 0.81 ± 0.10 mV in the presence VT158; from 0.92 ± 0.11 mV in the absence to 0.92 ± 0.11 mV in the presence VT160; from 0.82 ± 0.04 mV in the absence to 0.80 ± 0.05 mV in the presence VT163). In addition, all the A_3 agonists tested prevented or significantly delayed AD after 7-min OGD (not shown).

In a different experimental protocol, 10 nM Cl-IB-MECA was superfused for 15 min and up to 20 min before application of 7-min OGD. As shown in Fig. 2D, 10-nM Cl-IB-MECA did not change the fEPSP amplitude under normoxia (from 0.90 ± 0.09 mV before to 0.95 ± 0.10 in the presence of Cl-IB-MECA, $n=3$), but allowed a significant fEPSP recovery after 7-min OGD ($103.0 \pm 3.6\%$, $n = 3$, versus $4.1 \pm 3.6\%$, $n = 3$, recorded in non pretreated Cl-IB-MECA slices).

3.3. Selective block of A_3 adenosine receptors by MRS1523 reduces fEPSP depression evoked by 2-min OGD and induces a faster recovery of fEPSP amplitude after 5-min OGD

The data in Fig. 3 show that periods of 2- or 5-min OGD induced, respectively, a partial or complete reduction of synaptic potential amplitude that was always reversible upon reperfusion with normal oxygenated aCSF. These results are in agreement with our previous studies [13, 27,28].

The application of 2-min OGD resulted in a partial but consistent depression of synaptic potentials, reaching a maximal inhibition of $76.3 \pm 4.2\%$ ($n = 13$, $P < 0.001$, paired two-tailed Student's t test versus preischemic baseline) a few seconds after reperfusion with normal oxygenated aCSF (Fig. 3A). After 2 min of reperfusion in normal, glucose-containing aCSF, fEPSPs progressively reappeared and reached a complete recovery within 5 min after the beginning of reperfusion. The application of a second period of 2-min OGD, 40 min after the end of the first one, resulted in a similar depression ($66.4 \pm 6.2\%$) of fEPSP amplitude, with the same time course. No significant differences were found by comparing synaptic potential amplitude at any time during the first and second OGD (Fig. 3A). Therefore, the effect of the A_3 selective antagonist MRS1523 on fEPSPs was evaluated before and during the second period of 2-min OGD in comparison with the first OGD insult (Fig. 3B). MRS1523 (100 nM, $n = 10$) applied 10 min before, during, and 5 min after OGD did not modify fEPSP amplitude in normoxic conditions (from 0.90 ± 0.04 mV in the absence to 0.92 ± 0.04 in the presence of 100 nM MRS1523) but significantly inhibited fEPSP amplitude depression evoked by 2-min OGD ($74.1 \pm 6.1\%$ in the absence and $34.3 \pm 10.0\%$ in the presence of the antagonist, $P < 0.05$, paired two-tailed Student's t test, Fig. 3B). The effect of 100 nM MRS1523 was maximal, because the increase of the antagonist concentration to 1 μ M did not potentiate the effect ($n = 3$, data not shown).

Application of 5-min OGD resulted in a complete depression of synaptic potentials, reaching a maximal inhibition ~ 4 min after OGD application ($n = 12$, Fig. 3C). After 3.5 min of reperfusion in normal, glucose-containing aCSF, fEPSPs progressively reappeared and reached a complete recovery within 10 min from the beginning of reperfusion. Because it has been demonstrated that a second 5-min OGD episode, 50 min after the end of the first one, is followed by an appreciably faster recovery of fEPSPs [27], the effect of the selective A_3 antagonist was studied in a separate group of slices. MRS1523 (100 nM, $n = 7$), applied 10 min before, during, and 5 min after OGD application. The A_3 antagonist did not modify fEPSP amplitude in normoxic conditions (from 0.9 ± 0.04 mV in the absence to 1.0 ± 0.04 in the presence of 100 nM MRS1523) but induced a faster fEPSPs recovery (AUC: 10.1 ± 0.5 min in untreated OGD slices and 7.1 ± 0.7 min in the presence of the antagonist, $P < 0.05$, one-way ANOVA, Newman-

Keuls multiple-comparison post hoc test), measured from the beginning of fEPSP depression during OGD up to the recovery of fEPSP at baseline (Fig. 3C).

3.4. Selective stimulation of adenosine A₃ receptors by a long application of CI-IB-MECA reduces fEPSP depression evoked by 2-min OGD and induces a faster recovery of fEPSP amplitude after 5-min OGD

The effect of CI-IB-MECA (10 nM) on fEPSP amplitude after 2-min OGD is shown in Fig. 4A. The selective A₃ agonist did not affect the amplitude of fEPSPs under normoxic conditions (from 0.93 ± 0.07 mV in the absence to 0.96 ± 0.07 mV in the presence of 10 nM CI-IB-MECA, $n=13$), but induced a significant decrease in fEPSP depression evoked by 2-min OGD ($72.5 \pm 4.5\%$ in control and $39.5 \pm 7.1\%$ in the presence of the agonist, $n = 13$, $P < 0.05$, paired two-tailed Student's t test). The effect of 10 nM CI-IB-MECA was maximal, because the increase of the agonist concentration to 100 nM did not potentiate the effect ($75.1 \pm 7.3\%$ in control and $41.2 \pm 10.0\%$ in the presence of the agonist, $n = 6$, $P < 0.05$, paired two-tailed Student's t test, data not shown). The effect of 10 nM CI-IB-MECA was not antagonized by the selective A_{2A} receptor antagonist 4-(2-[7-amino-2-(2-furyl)(1,2,4)triazolo(2,3-a)(1,3,5)triazin-5-ylamino]ethyl)phenol (ZM241385), superfused 15 min before CI-IB-MECA and then coapplied with CI-IB-MECA ($73.4 \pm 9.1\%$ in the absence and $38.0 \pm 14.2\%$ in the presence of 100 nM ZM241385 in combination with CI-IB-MECA, $n = 3$, data not shown).

The effect of 10 nM CI-IB-MECA during 5-min OGD is shown in Fig. 4B. CI-IB-MECA did not change the fEPSP time course before (from 1.0 ± 0.06 min in the absence to 1.1 ± 0.07 min in the presence of CI-IB-MECA) and during OGD but reduced the time of fEPSP recovery (AUC: 9.5 ± 0.6 min in untreated OGD slices, $n = 10$, and 7.7 ± 0.6 min in the presence of the agonist, $n = 6$, $P < 0.05$, one-way ANOVA, Newman-Keuls multiple-comparison post hoc test).

Fig. 4C and D show the effect of coapplication of CI-IB-MECA and MRS1523 on 2- and 5-min OGD, respectively. The antagonist was always superfused 5 min before the agonist. The effect of the coapplication of the two drugs on fEPSP depression induced by 2-min OGD ($81.0 \pm 3.3\%$ in the absence and $32.3 \pm 11.5\%$ in the presence of the two drugs, $n = 7$, $P < 0.05$, paired two-tailed Student's t test, Fig. 4C) was not significantly different from those observed in the presence either of MRS1523 alone (Fig. 3B) or CI-IB-MECA alone (Fig. 4A). Similarly, the effect induced by the coapplication of the two drugs on the time of fEPSP recovery after 5-min OGD (AUC: 10.6 ± 1 min in untreated OGD slices, $n = 8$, and 7.8 ± 0.5 min in the presence of the two drugs, $n = 6$, $P < 0.05$, one-way ANOVA, Newman-Keuls multiple-comparison post hoc test) was not different from those observed in the presence of either MRS1523 alone (Fig. 3C) or CI-IB-MECA alone (Fig. 4B). The coapplication of the two drugs, MRS1523 and CI-IB-MECA, did not change the fEPSP amplitude under normoxic conditions (from 0.92 ± 0.03 mV in the absence to 0.94 ± 0.04 mV in the presence of the two drugs, $n=13$).

3.5. Selective stimulation of adenosine A₃ receptors by a short application of CI-IB-MECA did not affect fEPSP depression evoked by 2-min OGD and delayed the recovery of fEPSP amplitude after 5-min OGD

Because it has been demonstrated that A₃ adenosine receptors undergo a rapid desensitization that is more evident and persistent when the agonist is applied for long periods [20], we chose to examine a different protocol, shortening the time of CI-IB-MECA application. As shown in Fig. 5A, CI-IB-MECA (10 nM), applied only during the 2 min of OGD application, did not modify the outcome of fEPSP depression induced by 2-min OGD from that obtained in the absence of drug ($51.6 \pm 7.7\%$ in the absence and $55.6 \pm 11.8\%$ in the presence of CI-IB-MECA, $n = 7$). The data in Fig. 5B show that when CI-IB-MECA was applied for 2 min at the end of an OGD episode of 5-min duration, it significantly delayed the time of fEPSP recovery (AUC: 9.7 ± 0.4 min in untreated OGD slices, $n = 20$, and 12.1 ± 0.7 min in the presence of the agonist,

n = 10, $P < 0.05$, one-way ANOVA, Newman-Keuls multiple-comparison post hoc test). Similar results were obtained with different A₃ agonists: AR132 (10 nM, n = 3), VT158 (5 nM, n = 2), and VT160 (5 nM, n = 2, data not shown). A summary of short and long application of CI-IB-MECA during 5-min OGD is illustrated in Fig. 5C.

4. Discussion

Our results indicate that A₃ adenosine receptors play a role in neurotransmission of the CA1 region of the rat hippocampus during ischemia. A₃ adenosine receptor antagonists facilitate the recovery of otherwise disrupted neurotransmission after a period of prolonged OGD, and during short periods of OGD they decrease the depression of neurotransmission brought about by OGD. Selective stimulation of A₃ receptors, before and during an ischemic episode, produces changes in synaptic activity similar to those observed following their selective antagonism, indicating that A₃ receptors undergo rapid desensitization following exposure to exogenous agonist.

The application of prolonged (7-min) OGD elicited a complete and irreversible depression of neurotransmission, which persists upon slice reperfusion with oxygenated and glucose-containing aCSF and is accompanied by the appearance of AD, an unequivocal sign of neuronal injury during ischemia [26]. Here we report that two selective A₃ receptor antagonists, the newly synthesized LJ1251 [33] and MRS1523 share an equal effect. Both drugs in fact block the occurrence of AD and significantly protect from the irreversible disruption of excitatory neurotransmission caused by prolonged, severe (7-min) OGD episodes. These results are consistent with those obtained in the same brain region when different A₃ antagonists were used [14]. LJ1251 and MRS 1523 possess high affinity for the rat A₃ receptors ($K_i = 3.89$ nM [33] and 113 nM [31], respectively). The apparent discrepancy between the EC₅₀ value of LJ1251 (0.037 nM) found in our experiments and the binding K_i value of the compound, might depend on the specific environment and coupling of A₃ receptors in the cell membrane of native tissue and may differ from that assessed in receptor binding experiments. Alternatively, the paucity of A₃ receptors in native tissue [6] allows one to speculate that occupancy of a substantial fraction of A₃ receptors is required for evoking cell response(s). Thus, blocking a relatively small fraction of A₃ receptors may be sufficient to antagonize the effect of endogenous adenosine released during OGD. Alterations in AD characteristics caused by A₃ antagonists may be attributable to their actions on glutamate-mediated cellular responses. The time window of A₃ receptor-mediated effects found in the present work and reported by Pugliese et al [14] overlaps with the delay that can be obtained by treating the slices with glutamate receptor antagonists [25,40,41]. NMDA receptors are essential to AD initiation and propagation [26]. Block of A₃ receptors, in removing A₃ receptor-mediated impairment of the feedback inhibition of glutamate release exerted by specific metabotropic glutamate receptor subtypes [42], may reduce the participation of glutamate in triggering the AD.

Unlike the A₃ antagonists, the selective A₁ receptor antagonist DPCPX impairs the recovery of synaptic potentials after a hypoxic insult [43]. In rats *in vivo* the nonselective adenosine receptor antagonist theophylline increases the incidence of spreading depression, the analogue of AD in normoxic conditions, and decreases the latency of spreading-depression occurrence elicited by microdialysis of high K⁺ perfusate through the hippocampal CA1 area [44]. Moreover, it has been demonstrated that the block of A₁ receptors by theophylline or CPT (8-cyclopentyl-1,3-dimethylxanthine) shortens the onset of AD evoked by hypoxia in the CA1 region of gerbil hippocampal slices [45]. Therefore, during a prolonged severe OGD insult, the roles of A₁ and A₃ receptors drastically diverge. On the whole, the data support the well-established neuroprotective role of A₁ receptors [9,12,41] and confirm an opposite, deleterious, role of A₃ receptors during prolonged ischemia [14].

We then demonstrated that the block of A₃ receptors by the selective A₃ receptor antagonist MRS1523 reduces fEPSP inhibition caused by 2-min OGD and induces a faster recovery of fEPSP amplitude after 5-min OGD application. Unlike prolonged (7-min) OGD, depression of synaptic responses caused by OGD episodes of short duration (2 or 5 min) is fully reversible [13,27,28] and is not sufficient to trigger AD. The decrease in fEPSP depression or the faster recovery of fEPSP amplitude during the selective block of A₃ receptors indicates an inhibitory role of A₃ receptors on synaptic transmission during brief OGD. We previously demonstrated that depression of synaptic potentials during 2- or 5-min OGD is almost completely antagonized in the presence of the selective A₁ adenosine receptor antagonist DPCPX [10, 27,28]. Most of the known neuroprotective effects of adenosine during ischemia both *in vivo* and *in vitro* are attributed to the depression of synaptic activity induced by the activation of A₁ receptors. Therefore, the decrease in synaptic depression brought about by A₃ adenosine receptor antagonists suggests that A₁ and A₃ receptors cooperate in inhibiting fEPSP amplitude during the first minutes of OGD and share a neuroprotective role in these pathological conditions. This interpretation is in line with the observation that selective activation of A₃ adenosine receptors under hypoxic conditions brings about inhibition of excitatory neurotransmission in rat cortical neurons [22] and that mice lacking A₃ adenosine receptors have increased neurodegeneration in response to repeated episodes of moderate hypoxia [23].

Prolonged ischemic conditions could play a pivotal role in switching the effects of A₃ receptor stimulation from A₁-like inhibition to potentiation of an excitotoxic glutamate effect. The activation of phospholipase C by adenosine A₃ receptors has been reported in striatal and hippocampal slices [46]. Rat cortical neurons exposed to hypoxia *in vitro* show an increase in activation of protein kinase C (PKC) after selective A₃ receptor stimulation [47]. Similarly to what is described in the heart, PKC-dependent activation of K_{ATP} channels may enhance adenosine protection [48], but if OGD is applied long enough to be considered severe, protracted PKC activation induced by A₃ receptors could account for an increase in intracellular calcium, which may participate in increasing tissue excitability and thus lead to irreversible synaptic failure.

Unexpectedly, our results show that the effects induced by Cl-IB-MECA, during OGD of different durations, are similar to those elicited by adenosine A₃ antagonists. Cl-IB-MECA reduces fEPSP depression induced by 2-min OGD, induces a faster recovery of fEPSPs after 5-min OGD, and permits a full recovery of neurotransmission after prolonged (7-min) OGD. A decrease in fEPSP depression, brought about by A₃ agonists, hypothetically might be attributed to A_{2A} receptor stimulation. It was, in fact, previously demonstrated that selective stimulation of A_{2A} receptors by CGS 21680 decreases fEPSP depression induced by 2-min OGD and that the effect is antagonized by the selective A_{2A} antagonist ZM 241385 [28]. However, the concentration of Cl-IB-MECA used in the present study (10 nM) is highly selective for A₃ versus A_{2A} receptors [32], and the effect of Cl-IB-MECA is not antagonized by ZM 241385, indicating that Cl-IB-MECA-induced depression of fEPSP inhibition during 2-min OGD is not mediated by A_{2A} adenosine receptors. Specific involvement of A₃ receptors in the observed effects is also indicated by the observation that five chemically related compounds demonstrated similar effects to those elicited by Cl-IB-MECA. Moreover, the concentrations of Cl-IB-MECA and of MRS1523 used in the present study induce maximal effects. Therefore, the observation that the effects of Cl-IB-MECA and MRS1523 during 2- or 5- min OGD are not additive indicates that the effect of both drugs on fEPSP depression evoked by OGD is mediated by the same system (i.e., A₃ receptors).

A reducing effect of Cl-IB-MECA on fEPSPs inhibition induced by adenosine has been attributed to a desensitization of A₁ receptors [49]. Our results do not support such a mechanism because (i) the selective A₃ receptor antagonist MRS1523 not only does not potentiate fEPSP inhibition induced by 2- and 5-min OGD but attenuates this effect and (ii) Cl-IB-MECA

protects against AD appearance and irreversible disruption of excitatory neurotransmission caused by prolonged (7-min) OGD episodes, whereas A₁ antagonism shortens the onset of AD evoked by hypoxia [43].

Therefore, the effects of CI-IB-MECA are likely attributable to a rapid desensitization of A₃ receptors. Further evidence in support of A₃ desensitization is provided by the observation that the perfusion protocol of 15 min CI-IB-MECA application still allows a significant recovery of neurotransmission when it was applied 20 min before 7-min OGD. It is worth noting that when CI-IB-MECA was applied for a short time, it induced a slower recovery of fEPSPs after 5-min OGD instead of shortening the recovery as after long application. This indicates that a short application of CI-IB-MECA is not sufficient to trigger receptor desensitization. The adenosine A₃ receptor is particularly susceptible to phosphorylation by G protein-coupled receptor kinases [17,50]. Studies using CHO cells stably expressing the A₃ receptors have demonstrated that, following a few minutes of exposure to the agonist, there is rapid phosphorylation of the A₃ receptor, a reduction in number of A₃ high affinity agonist binding sites [16], and receptor internalization [19]. In human astrocytoma cells, brief exposure (1-60 min) to nanomolar concentrations of CI-IB-MECA results in a rapid uncoupling of A₃ receptors and receptor internalization while a long-lasting (1-24 h) CI-IB-MECA treatment leads to receptor down-regulation which recovers after several hours [20]. On this basis, in our experiments, 9 to 15 min of treatment with CI-IB-MECA likely produces uncoupling and internalization of the A₃ receptor. However, we cannot exclude subsequent down-regulation of receptor.

When considering that A₃ receptors encounter desensitization after prolonged exposure to A₃ agonists, we also have to consider that, under the OGD conditions used in the present study, endogenous adenosine released by the ischemic stimulus is not sufficient to cause A₃ receptor desensitization. During hypoxic/ischemic conditions, adenosine is released from hippocampal slices, reaching concentrations up to 30 μ M after 5-min OGD [10,41]. However, the efficacy of A₃ antagonists in blocking the depression induced by OGD of different durations indicates that endogenous adenosine concentrations reached in the extracellular milieu alone are not sufficient to desensitize A₃ receptors. Therefore, a stimulation as massive as that reached in the presence of endogenous adenosine plus exogenous A₃ agonists is necessary to induce substantial A₃ receptor plastic adjustments.

Conclusions

Our data indicate that the block of A₃ receptors, stimulated by adenosine released during ischemia, counteracts fEPSP depression induced by OGD of different durations. A novel A₃ antagonist, LJ1251, is protective at very low concentrations. Adenosine A₃ receptors stimulated by adenosine released during brief periods of ischemia might exert A₁-like protective effects on neurotransmission. Prolonged periods of ischemia would transform the A₃ receptor-mediated effects from protective to injurious. Moreover, our data support the notion that A₃ receptors undergo desensitization during exposure to an exogenous A₃ agonist.

Increased knowledge of molecular mechanisms of A₃ receptors during cerebral ischemia may increase our understanding of the utility of selective A₃ agonists/antagonists for treatment of ischemic and other neurodegenerative disorders.

Acknowledgements

This work was supported by grants from the University of Florence, the "Fondazione Monte del Paschi di Siena", Siena, Italy and the Italian Ministry of Health (MIUR) and by the NIDDK Intramural Research Program, National Institutes of Health (Bethesda, MD, USA).

References

1. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. *Pharmacol Rev* 2001;53:527–552. [PubMed: 11734617]
2. Zhou QY, Li C, Olah ME, Johnson RA, Stiles GL, Civelli O. Molecular cloning and characterization of an adenosine receptor: the A₃ adenosine receptor. *Proc Natl Acad Sci USA* 1992;89:7432–7436. [PubMed: 1323836]
3. Dixon AK, Gubitzi AK, Sirinathsinghji DJ, Richardson PJ, Freeman TC. Tissue distribution of adenosine receptor mRNAs in the rat. *Br J Pharmacol* 1996;118:1461–1468. [PubMed: 8832073]
4. Diaz-Hernandez M, Pereira MF, Pintor J, Cunha RA, Ribeiro JA, Miras-Portugal MT. Modulation of the rat hippocampal dinucleotide receptor by adenosine receptor activation. *J Pharmacol Exp Ther* 2002;301:441–450. [PubMed: 11961042]
5. Lopes LV, Rebola N, Pinheiro PC, Richardson PJ, Oliveira CR, Cunha RA. Adenosine A₃ receptors are located in neurons of the rat hippocampus. *Neuroreport* 2003;14:1645–1648. [PubMed: 14502093]
6. Ji XD, Gallo-Rodriguez C, Jacobson KA. A selective agonist affinity label for A₃ adenosine receptors. *Biochem Biophys Res Commun* 1994;203:570–576. [PubMed: 8074705]
7. Cunha RA, Constantino MC, Sebastiao AM, Ribeiro JA. Modification of A₁ and A_{2A} adenosine receptor binding in aged striatum, hippocampus and cortex of the rat. *Neuroreport* 1995;6:1583–1588. [PubMed: 7579154]
8. Cunha RA, Johansson B, Constantino MD, Sebastiao AM, Fredholm BB. Evidence for high-affinity binding sites for the adenosine A_{2A} receptor agonist [³H]CGS 21680 in the rat hippocampus and cerebral cortex that are different from striatal A_{2A} receptors. *Naunyn Schmiedeberg Arch Pharmacol* 1996;353:261–271. [PubMed: 8692280]
9. Latini S, Pedata F. Adenosine in the central nervous system: release mechanisms and extracellular concentrations. *J Neurochem* 2001;79:463–484. [PubMed: 11701750]
10. Latini S, Bordoni F, Corradetti R, Pepeu G, Pedata F. Temporal correlation between adenosine outflow and synaptic potential inhibition in rat hippocampal slices during ischemia-like conditions. *Brain Res* 1998;794:325–328. [PubMed: 9622666]
11. Jacobson KA. Adenosine A₃ receptors: novel ligands and paradoxical effects. *Trends Pharmacol Sci* 1998;19:184–191. [PubMed: 9652191]
12. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. *Nat Rev Drug Discov* 2006;5:247–264. [PubMed: 16518376]
13. Pugliese AM, Latini S, Corradetti R, Pedata F. Brief, repeated, oxygen-glucose deprivation episodes protect neurotransmission from a longer ischemic episode in the in vitro hippocampus: role of adenosine receptors. *Br J Pharmacol* 2003;140:305–314. [PubMed: 12970092]
14. Pugliese AM, Coppi E, Spalluto G, Corradetti R, Pedata F. A₃ adenosine receptor antagonists delay irreversible synaptic failure caused by oxygen and glucose deprivation in the rat CA1 hippocampus in vitro. *Br J Pharmacol* 2006;147:524–532. [PubMed: 16415905]
15. von Lubitz DK, Lin RC, Popik P, Carter MF, Jacobson KA. Adenosine A₃ receptor stimulation and cerebral ischemia. *Eur J Pharmacol* 1994;263:59–67. [PubMed: 7821362]
16. Palmer TM, Benovic JL, Stiles GL. Agonist-dependent phosphorylation and desensitization of the rat A₃ adenosine receptor. Evidence for a G-protein-coupled receptor kinase-mediated mechanism. *J Biol Chem* 1995;270:29607–29613. [PubMed: 7494005]
17. Palmer TM, Stiles GL. Identification of threonine residues controlling the agonist-dependent phosphorylation and desensitization of the rat A₃ adenosine receptor. *Mol Pharmacol* 2000;57:539–545. [PubMed: 10692494]
18. Ferguson G, Watterson KR, Palmer TM. Subtype-specific kinetics of inhibitory adenosine receptor internalization are determined by sensitivity to phosphorylation by G protein-coupled receptor kinases. *Mol Pharmacol* 2000;57:546–552. [PubMed: 10692495]
19. Trincavelli ML, Tuscano D, Cecchetti P, Falleni A, Benzi L, Klotz KN, Gremigni V, Cattabeni F, Lucacchini A, Martini C. Agonist-induced internalization and recycling of the human A₃ adenosine receptors: role in receptor desensitization and resensitization. *J Neurochem* 2000;75:1493–1501. [PubMed: 10987829]

20. Trincavelli ML, Tuscano D, Marroni M, Falleni A, Gremigni V, Ceruti S, Abbracchio MP, Jacobson KA, Cattabeni F, Martini C. A₃ adenosine receptors in human astrocytoma cells: agonist-mediated desensitization, internalization, and down-regulation. *Mol Pharmacol* 2002;62:1373–1384. [PubMed: 12435805]
21. Trincavelli ML, Tuscano D, Marroni M, Klotz KN, Lucacchini A, Martini C. Involvement of mitogen protein kinase cascade in agonist-mediated human A₃ adenosine receptor regulation. *Biochim Biophys Acta* 2002;1591:55–62. [PubMed: 12183055]
22. Hentschel S, Lewerenz A, Nieber K. Activation of A₃ receptors by endogenous adenosine inhibits synaptic transmission during hypoxia in rat cortical neurons. *Restor Neurol Neurosci* 2003;21:55–63. [PubMed: 12808203]
23. Fedorova IM, Jacobson MA, Basile A, Jacobson KA. Behavioral characterization of mice lacking the A₃ adenosine receptor: sensitivity to hypoxic neurodegeneration. *Cell Mol Neurobiol* 2003;23:431–447. [PubMed: 12825837]
24. Chen GJ, Harvey BK, Shen H, Chou J, Victor A, Wang Y. Activation of adenosine A₃ receptors reduces ischemic brain injury in rodents. *J Neurosci Res* 2006;84:1848–1855. [PubMed: 17016854]
25. Tanaka E, Yamamoto S, Kudo Y, Mihara S, Higashi H. Mechanisms underlying the rapid depolarization produced by deprivation of oxygen and glucose in rat hippocampal CA1 neurons in vitro. *J Neurophysiol* 1997;78:891–902. [PubMed: 9307122]
26. Somjen GG. Mechanisms of spreading depression and hypoxic spreading depression-like depolarization. *Physiol Rev* 2001;81:1065–1096. [PubMed: 11427692]
27. Latini S, Bordoni F, Pedata F, Corradetti R. Extracellular adenosine concentrations during in vitro ischaemia in rat hippocampal slices. *Br J Pharmacol* 1999;127:729–739. [PubMed: 10401564]
28. Latini S, Bordoni F, Corradetti R, Pepeu G, Pedata F. Effect of A_{2A} adenosine receptor stimulation and antagonism on synaptic depression induced by in vitro ischaemia in rat hippocampal slices. *Br J Pharmacol* 1999;128:1035–1044. [PubMed: 10556941]
29. Anderson WW, Collingridge GL. The LTP Program: a data acquisition program for on-line analysis of long-term potentiation and other synaptic events. *J Neurosci Methods* 2001;108:71–83. [PubMed: 11459620]
30. Pedata F, Latini S, Pugliese AM, Pepeu G. Investigations into the adenosine outflow from hippocampal slices evoked by ischemia-like conditions. *J Neurochem* 1993;61:284–289. [PubMed: 8515275]
31. Li AH, Moro S, Melman N, Ji XD, Jacobson KA. Structure-activity relationships and molecular modeling of 3, 5-diacetyl-2,4-dialkylpyridine derivatives as selective A₃ adenosine receptor antagonists. *J Med Chem* 1998;41:3186–3201. [PubMed: 9703464]
32. Müller CE. Medicinal chemistry of adenosine A₃ receptor ligands. *Curr Top Med Chem* 2003;3:445–462. [PubMed: 12570761]
33. Jeong LS, Choe SA, Gunaga P, Kim HO, Lee HW, Lee SK, Tosh D, Patel A, Palaniappan KK, Gao ZG, Jacobson KA, Moon HR. Discovery of a new nucleoside template for human A₃ adenosine receptor ligands: Truncated 4'-tihoadenosine derivatives as highly potent and selective antagonists. *J Med Chem*. 2007in press
34. Jacobson KA, Siddiqi SM, Olah ME, Ji XD, Melman N, Bellamkonda K, et al. Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A₃ adenosine receptors. *J Med Chem* 1995;38:1720–1735. [PubMed: 7752196]
35. Kim HO, Ji XD, Melman N, Olah ME, Stiles GL, Jacobson KA. Selective ligands for rat A₃ adenosine receptors: structure-activity relationships of 1,3-dialkylxanthine 7-riboside derivatives. *J Med Chem* 1994;37:4020–4030. [PubMed: 7966162]
36. Volpini R, Costanzi S, Lambertucci C, Taffi S, Vittori S, Klotz KN, Cristalli G. N⁶-Alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A₃ receptor and a starting point for searching A_{2B} ligands. *J Med Chem* 2002;45:3271–3279. [PubMed: 12109910]
37. Volpini R, Lambertucci C, Taffi S, Vittori S, Klotz KN, Cristalli G. A₃ adenosine receptors: synthesis and biological evaluation of new potent and selective ligands. *Collection Symposium Series* 2005;7:297–300.

38. Dal Ben D, Lambertucci C, Taffi S, Vittori S, Volpini R, Klotz KN, Cristalli G. Molecular modeling study of 2-phenylethynyladenosine (PEAdo) derivatives as highly selective A₃ adenosine receptor ligands. *Purinergic Signalling* 2006;2:589–594.
39. Volpini R, Dal Ben D, Lambertucci C, Taffi S, Vittori S, Klotz KN, Cristalli G. N⁶-Methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A₃ adenosine receptor. *J Med Chem* 2007;50:1222–1230. [PubMed: 17309246]
40. Yamamoto S, Tanaka E, Shoji Y, Kudo Y, Inokuchi H, Higashi H. Factors that reverse the persistent depolarization produced by deprivation of oxygen and glucose in rat hippocampal CA1 neurons in vitro. *J Neurophysiol* 1997;78:903–911. [PubMed: 9307123]
41. Pearson T, Damian K, Lynas RE, Frenguelli BG. Sustained elevation of extracellular adenosine and activation of A₁ receptors underlie the post-ischaemic inhibition of neuronal function in rat hippocampus in vitro. *J Neurochem* 2006;97:1357–1368. [PubMed: 16696848]
42. Macek TA, Schaffhauser H, Conn PJ. Protein kinase C and A₃ adenosine receptor activation inhibit presynaptic metabotropic glutamate receptor (mGluR) function and uncouple mGluRs from GTP-binding proteins. *J Neurosci* 1998;18:6138–6146. [PubMed: 9698308]
43. Sebastiao AM, de Mendonca A, Moreira T, Ribeiro JA. Activation of synaptic NMDA receptors by action potential-dependent release of transmitter during hypoxia impairs recovery of synaptic transmission on reoxygenation. *J Neurosci* 2001;21:8564–8571. [PubMed: 11606644]
44. Kaku T, Hada J, Hayashi Y. Endogenous adenosine exerts inhibitory effects upon the development of spreading depression and glutamate release induced by microdialysis with high K⁺ in rat hippocampus. *Brain Res* 1994;658:39–48. [PubMed: 7834353]
45. Lee KS, Lowenkopf T. Endogenous adenosine delays the onset of hypoxic depolarization in the rat hippocampus in vitro via an action at A₁ receptors. *Brain Res* 1993;609:313–315. [PubMed: 8508312]
46. Abbracchio MP, Brambilla R, Ceruti S, Kim HO, von Lubitz DK, Jacobson KA, Cattabeni F. G protein-dependent activation of phospholipase C by adenosine A₃ receptors in rat brain. *Mol Pharmacol* 1995;48:1038–1045. [PubMed: 8848003]
47. Nieber, K.; Hentschel, S. Signalling pathways of the adenosine A₃ receptors in rat cortical neurons. *Proceedings of the 8th International Symposium on adenosine and adenine nucleotides; Ferrara, Italy. May 24-28, 2006;*
48. Liang BT. Protein kinase C-dependent activation of K_{ATP} channel enhances adenosine-induced cardioprotection. *Biochem J* 1998;336:337–343. [PubMed: 9820809]
49. Dunwiddie TV, Diao L, Kim HO, Jiang JL, Jacobson KA. Activation of hippocampal adenosine A₃ receptors produces a desensitization of A₁ receptor-mediated responses in rat hippocampus. *J Neurosci* 1997;17:607–614. [PubMed: 8987783]
50. Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. *Ann Rev Pharmacol Toxicol* 2001;41:775–787. [PubMed: 11264476]

Abbreviations

AD	anoxic depolarization
aCSF	artificial cerebral spinal fluid
AR132	N ⁶ -methyl-2-phenylethynyladenosine
AUC	area under curve
CHO	Chinese hamster ovary

CI-IB-MECA

1-[2-chloro-6-[[[3-iodophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl-β-D-ribofuranuronamide

DMSO

dimethylsulfoxide

fEPSP

field excitatory post synaptic potential

LJ1251

(2*R*,3*R*,4*S*)-2-(2-chloro-6-(3-iodobenzylamino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol

MRS1523

3-propyl-6-ethyl-5-[(ethylthio)carbonyl]-2-phenyl-4-propyl-3-pyridine carboxylate

OGD

oxygen glucose deprivation

PKC

protein kinase C

SD

spreading depression

VT72

N⁶-methoxy-2-phenylethynyladenosine

VT158

N⁶-methoxy-2-phenylethynyl-5'-N-methylcarboxamidoadenosine

VT160

N⁶-methoxy-2-(2-pyridinyl)-ethynyl-5'-N-methylcarboxamidoadenosine

VT163

N⁶-methoxy-2-*p*-acetylphenylethynyl-5'-N-methylcarboxamidoadenosine

ZM241385

4-(2-[7-amino-2-(2-furyl)(1,2,4)triazolo(2,3-*a*)(1,3,5)triazin-5-yl amino]ethyl)phenol

Fig 1.

The selective A₃ adenosine receptor antagonists, LJ1251 and MRS1523, minimized AD and protected CA1 hippocampus from irreversible fEPSP depression induced by 7-min OGD. (A) AD, was recorded as the negative d.c. shift in response to 7-min OGD (solid bar) in the absence (n = 13, left panel), and in the presence of 10 nM LJ1251 (open bar, n = 5, middle panel) or 100 nM MRS1523 (open bar, n = 5, right panel). Note that both the A₃ antagonists LJ1251 and MRS1523 completely prevented AD appearance. (B) Graphs show the time course of 7-min OGD (solid bar) effect on fEPSP amplitude, expressed as percentage of baseline, in untreated OGD slices (filled circles, mean ± S.E.M., n = 13), in the presence of 10 nM LJ1251 (open circles, mean ± S.E.M., n = 5) and 100 nM MRS1523 (filled triangles, mean ± S.E.M.,

n=5). Solid bars indicate the duration of OGD. (C) Concentration-response curves of LJ1251. The graph shows the fitting curve of concentration-dependent effects of LJ1251 on fEPSP recovery after 7-min OGD recorded in hippocampal slices at 15-min reperfusion in normal, oxygenated aCSF. Data (mean $\pm$ S.E.M., n = 3 in 0.001 nM LJ1251, n = 3 in 0.01 nM, n = 3 in 0.1 nM, n = 4 in 5 nM, n = 5 in 10 nM) are expressed as percentage of baseline values. * P < 0.01, one-way ANOVA, Newman-Keuls multiple-comparison post hoc test, versus 0.001 and 0.01 nM LJ1251-treated slices.

Fig 2.

The selective A₃ adenosine agonist CI-IB-MECA protects hippocampal slices from the irreversible fEPSP depression induced by 7-min OGD.

(A) AD was recorded as the negative d.c. shift in response to 7-min OGD (solid bars) in the absence (n = 8) and in the presence of 10 nM CI-IB-MECA (open bar, n = 8). The agonist prevented AD appearance in 5 slices and delayed it in the remaining 3 slices. (B) Time course of fEPSP amplitude before, during 7-min OGD, and after reperfusion in normal oxygenated aCSF in the absence and in the presence of 10 nM CI-IB-MECA (open bar). Data (mean $\pm$ S.E.M., n = 16 in untreated OGD slices, n = 15 in CI-IB-MECA) are expressed as percentage of baseline values. CI-IB-MECA was applied 5 min before, during, and 2 min after OGD. (C) Columns in the graph summarize the effects of different A₃ agonists on fEPSP recovery after 7- min OGD. **P* < 0.05, one-way ANOVA followed by Newman-Keuls multiple-comparison post hoc test versus untreated OGD slices (D) Each graph shows the time course of fEPSP amplitude before and after 7-min OGD. Data (mean $\pm$ S.E.M., n = 3 for each experimental group) are expressed as percentage of baseline values. Note that in a group of slices OGD was applied 20 min after the end of CI-IB-MECA superfusion (open bar, 10 nM, 15 min). A complete recovery of fEPSP amplitude was obtained only in the slices in which OGD was applied after CI-IB-MECA application. Solid bars indicate the duration of OGD.

Fig 3.

The selective A₃ adenosine receptor antagonist MRS1523 reduces fEPSP depression induced by 2-min OGD and induced a faster recovery of fEPSP amplitude after 5-min OGD.

(A) Time course of fEPSP amplitude before, during, and after the application of two consecutive ischemic insults of 2-min duration. The second 2-min OGD, administered 40 min after the end of the first period, elicited a comparable depression of synaptic potentials ($P > 0.05$, evaluated by t -paired two-tailed Student's t test). Data (mean $\pm$ S.E.M., $n = 13$) are expressed as a percentage of baseline values recorded before the first OGD period. (B) Time course of fEPSP amplitude changes elicited by 2-min OGD in the absence and in the presence of MRS1523. Data (mean $\pm$ S.E.M., $n = 10$) are expressed as a percentage of baseline values. MRS1523 (100 nM) was applied 10 min before, during, and 5 min after OGD, as indicated by the open bar. Note that in the presence of MRS1523, the fEPSP depression induced by OGD was significantly lower than that obtained in the absence of the drug ($P < 0.05$, paired two-tailed Student's t test). (C) Time course of fEPSP amplitude changes elicited by 5-min OGD in the absence ($n = 12$) and in the presence of MRS1523 ($n = 7$). Data (mean $\pm$ S.E.M.) are expressed as a percentage of baseline values recorded before the respective OGD periods. MRS1523 (100 nM), applied 10 minutes before, during, and 5 minutes after OGD application induced a faster fEPSP recovery after OGD application. Solid bars indicate the duration of OGD.

Fig 4.

The selective A_3 adenosine receptor agonist CI-IB-MECA decreased fEPSP depression induced by 2-min OGD and induced a faster recovery of fEPSP amplitude after 5-min OGD. (A) Time-course of fEPSP amplitude changes elicited by 2-min OGD in the absence and in the presence of CI-IB-MECA (10 nM; n = 13). Data (mean $\pm$ S.E.M.) are expressed as a percentage of respective baseline values recorded before the respective OGD periods. The solid bar indicates the duration of OGD. As indicated by the open bar, the A_3 agonist was applied 5 min before, during, and 2 min after OGD. Note that in the presence of CI-IB-MECA, the fEPSP depression induced by 2-min OGD was significantly lower than that obtained in the absence of the drug ($P < 0.05$, paired two-tailed Student's t test). (B) Time course of fEPSP amplitude changes elicited by 5 min OGD in the absence (n = 10) and presence of CI-IB-MECA (10 nM, n = 6). Data (mean $\pm$ S.E.M.) are expressed as a percentage of baseline values recorded before the respective OGD periods. The A_3 agonist, applied 5 min before, during, and 2 min after OGD (open bar) induced a faster fEPSP recovery after 5 min OGD. (C) Time course of fEPSP amplitude changes elicited by 2-min OGD in the absence and presence of CI-IB-MECA (10 nM) in combination with MRS1523 (100 nM). The antagonist was always superfused 5 min before the agonist; coapplied with the agonist 5 min before, during, and 2 min after OGD; and then superfused alone for 3 min. Data (mean $\pm$ S.E.M., n = 7) are expressed as a percentage of the respective baseline values. Note that in the presence of CI-IB-MECA and MRS1523, the fEPSP depression induced by 2-min OGD was significantly lower than ($P < 0.05$, paired two-tailed Student's t test) that obtained in the absence of the drugs. (D) Time course of fEPSP amplitude changes elicited by 5 min OGD in the absence (n = 8) and presence of CI-IB-MECA (10 nM) in combination with MRS1523 (100 nM) (n = 6). As indicated by open bars, the antagonist was always superfused 5 min before the agonist; coapplied with the agonist 5 min

before, during and 2-min after OGD; and then superfused alone for 3 min. Data (mean $\pm$ S.E.M.) are expressed as a percentage of respective baseline values. Solid bars indicate the duration of OGD.

Fig 5.

Short application CI-IB-MECA did not modify fEPSP depression induced by 2-min OGD, but it significantly delays fEPSP recovery after 5-min OGD.

(A) Time course of fEPSP amplitude changes elicited by 2-min OGD in the absence and in the presence of CI-IB-MECA (10 nM, $n = 7$). Data (mean $\pm$ S.E.M.) are expressed as a percentage of respective baseline values recorded before the respective OGD periods. As indicated by the open bar, the A_3 agonist was applied for only 2 min, during OGD. Note that short application of CI-IB-MECA did not induce significant change ($P > 0.05$, paired two-tailed Student's t test) in the fEPSP depression induced by 2-min OGD. (B) Time course of fEPSP amplitude changes elicited by 5-min OGD in the absence ($n = 20$) and in the presence of CI-IB-MECA (10 nM,

n = 10). Data (mean $\pm$ S.E.M.) are expressed as a percentage of respective baseline values recorded before the respective OGD periods. As indicated by the open bar, the A₃ agonist was applied only for 2 min, at the end of 5-min OGD episodes. Note that short application of CI-IB-MECA delayed fEPSP recovery after 5 min OGD. (C) Columns in the graph summarize the average time of fEPSP amplitude recovery (mean $\pm$ S.E.M.) after 5-min OGD in untreated OGD slices and during long or short application of CI-IB-MECA. * $P < 0.05$, one-way ANOVA followed by Newman-Keuls multiple-comparison post hoc test versus untreated OGD slices; § $P < 0.05$, one-way ANOVA followed by Newman-Keuls multiple-comparison post hoc test versus all experimental groups. Solid bars indicate the duration of OGD.

xTable 1

Binding affinities of adenosine agonists and antagonists at three subtypes of ARs (human, unless noted; r = rat).^a Nucleoside structures are shown:

Compound	Affinity ($K_i \pm \text{SEM}$, nM)		
	A ₁	A _{2A}	A ₃
Agonists			
CI-IB-MECA	222 ± 22	5360 ± 2470	1.4 ± 0.3
AR132	820 (r)	470 (r)	0.33 (r)
VT72	1690	8530	3.4
VT158	1210	4290	3.8
VT160	9140	16,300	1.9
VT163	3990	18,000	1.1
VT163	53,800	10,400	2.5
Antagonists			
MRS1523	15,600 (r)	2050 (r)	18.9
LJ1251	2490 ± 940	341 ± 75	113 (r)
ZM241,385	774	1.6	4.16 ± 0.50
			3.89 ± 1.15 (r)
			743

a) K_i values were obtained from references [32], [33], [35-39].